Alyeska Investment Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Alyeska Investment Group’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.74M	Buy	+308,507	New	+$6.42M	0.02%	473
2023 Q1	–	Sell	-100,000	Closed	-$2.54M	–	538
2022 Q4	$2.54M	Buy	+100,000	New	+$2.33M	0.03%	304
2018 Q3	–	Sell	-338,789	Closed	-$2.38M	–	504
2018 Q2	$2.38M	Buy	338,789 +10,834	+3%	+$106K	0.02%	340
2018 Q1	$4.67M	Sell	327,955 -2,955	-0.9%	-$31.4K	0.04%	296
2017 Q4	$2.9M	Hold	330,910	–	–	0.02%	302
2017 Q3	$3.87M	Buy	330,910 +5,910	+2%	+$72.4K	0.03%	311
2017 Q2	$4.54M	Buy	325,000 +152,614	+89%	+$1.74M	0.04%	291
2017 Q1	$2.37M	Sell	172,386 -52,614	-23%	-$546K	0.02%	385
2016 Q4	$1.61M	Buy	225,000 +56,228	+33%	+$616K	0.01%	404
2016 Q3	$2.56M	Buy	168,772 +43,772	+35%	+$576K	0.02%	373
2016 Q2	$1.23M	Sell	125,000 -50,000	-29%	-$686K	0.01%	379
2016 Q1	$2.33M	Buy	+175,000	New	+$2.2M	0.02%	318

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Alyeska Investment Group's SNDX Position: Q2 2026 in Review

Alyeska Investment Group opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 308,507 shares worth $6.74M. The stake represents 0.02% of the portfolio and ranks #473 among its holdings. This is a return to the name: Alyeska Investment Group previously reported a position in SNDX as recently as Q4 2022.

Alyeska Investment Group first reported a position in SNDX in Q1 2016 and has held it in 12 quarters since. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Alyeska Investment Group held 308,507 shares of Syndax Pharmaceuticals worth $6.74M as of Q2 2026.
Syndax Pharmaceuticals was a new Alyeska Investment Group position in Q2 2026.
Syndax Pharmaceuticals made up 0.02% of Alyeska Investment Group's portfolio in Q2 2026, its #473 holding.
Alyeska Investment Group first reported a position in Syndax Pharmaceuticals in Q1 2016 and has held it in 12 quarters since.
243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.